case_images: PMC11034483_01
case_images: Immunohistochemistry studies of biopsy of metastatic tumor of unknown primary from the eighth and tenth thoracic vertebrae (T8 and T10) (A) Hematoxylin Eosin (H/E). 100x, showing clusters of large atypical cells with medium sized nucleoli and moderate amount of eosinophilic cytoplasm. (B) H/E, 400x (C) H/E, 600x (D) AE1/AE3 immunohistochemistry, 100x, showing diffuse and strongly positive staining of tumor cells. (E) CK7 immunohistochemistry. 100x, showing diffuse and strongly positive staining of tumor cells. (F) GATA-3 immunohistochemistry, 100x, showing diffuse and strongly positive staining of tumor cells.
case_images: fonc-14-1372382-g001.jpg
case_images: PMC11034483_01_fonc-14-1372382-g001.jpg
case_images: f1
case_images: AE1/AE3, CK7 and GATA-3 ( Figure 1 ), and were negative for PD-L1 (TPS <1%), TTF-1, p40, S-100, p53, PSA, NKX3.1, PAX-8, desmin and CDX-2. A subset of cells showed coexpression of SATB-2 and p63.
case_images: (A) E-cadherin immunohistochemistry, 100x, tumor cells are negative for E-cadherin. (B) AR immunohistochemistry. 200x, showing positive staining of tumor cells.
case_images: fonc-14-1372382-g002.jpg
case_images: PMC11034483_01_fonc-14-1372382-g002.jpg
case_images: f2
case_images: IHC was positive for CK7, GATA3, and AR ( Figure 2 ), which were similar to the previously diagnosed vertebral metastasis. Figure 4 ). Furthermore, E-cadherin immunohistochemistry of the cervical lymph node biopsy showed that tumor cells were negative for E-cadherin ( Figure 2 ).
case_images: A timeline of the treatments our patient received throughout his treatment course. Time from the start of the first line of therapy to the occurrence of first relapse (PFS1) was 5 months and overall survival was 17 months.
case_images: fonc-14-1372382-g003.jpg
case_images: PMC11034483_01_fonc-14-1372382-g003.jpg
case_images: f3
case_images: Time from the start of the first line of therapy to the occurrence of first relapse (PFS1) was 5 months ( Figure 3 ).
case_images: Molecular karyotype generated by detecting copy number gains and losses from next-generation sequencing data using CNVkit. More specifically, loss of heterozygosity (LOH) is seen on chromosome 16 at the CDH1 locus (chr16 q22.1) indicating that our patient had bi-allelic inactivation of the CDH1 gene.
case_images: fonc-14-1372382-g004.jpg
case_images: PMC11034483_01_fonc-14-1372382-g004.jpg
case_images: f4
case_images: These genome-wide copy number results were plotted graphically to generate the karyotype ( Figure 4 ). Figure 4 ). Furthermore, E-cadherin immunohistochemistry of the cervical lymph node biopsy showed that tumor cells were negative for E-cadherin ( Figure 2 ).